Pfizer (NYSE:PFE | PFE Price Prediction) trades at $25.62, pays a 6.7% dividend yield, and just posted five straight ...

The pharmaceutical outfit has taken a savvy step forward. Now it just needs to repeat the process a few more times.

Investors are clearly worried about the safety of Pfizer's dividend, which is reasonable.

By Maggie Fick, Bhanvi Satija and Patricia Weiss LONDON/FRANKFURT, June 10 (Reuters) - Pfizer is reviewing the timing and ...

Nausea and vomiting rates for the monthly injectable berobenatide came in close to benchmarks set by Novo Nordisk's weekly ...

Roche Holding AG and Pfizer Inc. are aggressively advancing obesity and T2D pipelines to capture share in the surging GLP-1 ...

Hympavzi is approved for routine prophylaxis to prevent bleeding episodes in US patients six years and above.

The biotech company doesn’t have any obesity drugs on the market. Here’s how it plans to change that, and become an industry ...

Pfizer shares may have found a more balanced risk-reward profile after a sharp decline this year, prompting RBC Capital Markets to upgrade the drugmaker to Sector Perform from Underperform while ...

By Michael Erman NEW YORK, June 6 (Reuters) - Pfizer presented data on Saturday that showed a monthly dose of an experimental ...

US pharmaceutical giant Pfizer has pulled out of a meeting with German Chancellor Friedrich Merz over plans to reform the ...

Chai Discovery is working with major drugmakers to use its latest antibody AI model to find new therapies. Now it’s in talks ...